2010 Fiscal Year Final Research Report
The chemotherapeutic strategy with a novel NF-kappa B inhibitor in bladder cancer
| Project/Area Number |
20591866
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
KIKUCHI Eiji Keio University, 医学部, 講師 (10286552)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIYAJIMA Akira 慶應義塾大学, 医学部, 講師 (90245572)
OYA Mototsugu 慶應義塾大学, 医学部, 教授 (00213885)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Keywords | 膀胱癌 / 転写因子 / 抗癌治療 |
|---|
| Research Abstract |
The present study was undertaken to assess the possibility of enhancement of chemosensitivity to CPT-11 by a novel and strong NF-κB inhibitor, DHMEQ in bladder cancer. Constitutive activation of NF-κB was observed in KU19-19 cells. NF-κB was activated by the treatment with SN38. However, pretreatment with DHMEQ inhibited the activation of NF-κB induced by SN-38. The combination treatment resulted in a significantly higher level of growth inhibition compared to treatment with DHMEQ or SN-38 alone. Chemotherapy in combination with DHMEQ might be a novel therapeutic modality against bladder cancer.
|
-
[Journal Article] Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.2010
Author(s)
Kodaira K, Kikuchi E, Kosugi M, Horiguchi Y, Matsumoto K, Kanai K, Suzuki E, Miyajima A, Nakagawa K, Tachibana M, Umezawa K, Oya M.
-
Journal Title
Urology 75
Pages: 805-812
Peer Reviewed
-
-
-
-
-
-
